SE435497B - 1,6-dimetylsulfonyl-3,4-dimetyl-d-mannitol, farmaceutisk beredning och forfarandet for framstellning derav - Google Patents
1,6-dimetylsulfonyl-3,4-dimetyl-d-mannitol, farmaceutisk beredning och forfarandet for framstellning deravInfo
- Publication number
- SE435497B SE435497B SE7903828A SE7903828A SE435497B SE 435497 B SE435497 B SE 435497B SE 7903828 A SE7903828 A SE 7903828A SE 7903828 A SE7903828 A SE 7903828A SE 435497 B SE435497 B SE 435497B
- Authority
- SE
- Sweden
- Prior art keywords
- mannitol
- dimethyl
- compound
- formula
- dimethylsulfonyl
- Prior art date
Links
- OHPIJHNCKQFIGN-YPRZEIDWSA-N (2s,3r,4r,5s)-3,4-dimethyl-1,6-bis(methylsulfonyl)hexane-1,2,3,4,5,6-hexol Chemical compound CS(=O)(=O)C(O)[C@@H](O)[C@](O)(C)[C@](C)(O)[C@H](O)C(O)S(C)(=O)=O OHPIJHNCKQFIGN-YPRZEIDWSA-N 0.000 title claims description 6
- 238000000034 method Methods 0.000 title claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000001085 cytostatic effect Effects 0.000 claims description 5
- 230000010933 acylation Effects 0.000 claims description 4
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- KKOBWNQHGWMYBG-WCTZXXKLSA-N (2r,3r,4r,5r)-3,4-dimethylhexane-1,2,3,4,5,6-hexol Chemical compound OC[C@@H](O)[C@](O)(C)[C@](C)(O)[C@H](O)CO KKOBWNQHGWMYBG-WCTZXXKLSA-N 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- -1 1,6-dimethyl-3,4-dimethyl-mannitol Chemical compound 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 3
- LJBKHHZPVCABCX-ZYUZMQFOSA-N [(2r,3r,4r,5r)-2,5-dihydroxy-3,4-dimethoxy-6-methylsulfonyloxyhexyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](O)[C@@H](OC)[C@H](OC)[C@H](O)COS(C)(=O)=O LJBKHHZPVCABCX-ZYUZMQFOSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- SRZHBUXJTKNDRG-WCTZXXKLSA-N (2r,3r,4r,5r)-3,4-dimethoxyhexane-1,2,5,6-tetrol Chemical compound OC[C@@H](O)[C@@H](OC)[C@H](OC)[C@H](O)CO SRZHBUXJTKNDRG-WCTZXXKLSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ODOISJJCWUVNDJ-WCTZXXKLSA-N [(2r,3r,4r,5r)-2,3,4,5-tetrahydroxy-6-methylsulfonyloxyhexyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(C)(=O)=O ODOISJJCWUVNDJ-WCTZXXKLSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000003328 mesylation reaction Methods 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- UQBNSDYXYHVZOD-UHFFFAOYSA-N (4-hydroxy-8-methyl-2-oxo-3,4-dihydropyrido[4,3-e][1,3]oxazin-5-yl)methyl dihydrogen phosphate Chemical compound OC1NC(=O)OC2=C1C(COP(O)(O)=O)=CN=C2C UQBNSDYXYHVZOD-UHFFFAOYSA-N 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 101000794282 Homo sapiens Putative protein C3P1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100030156 Putative protein C3P1 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KRWZZLLACQKPOW-AAVRWANBSA-N [(2r,3r,4r,5r)-5-acetyloxy-3,4-dimethoxy-1,6-bis(methylsulfonyloxy)hexan-2-yl] acetate Chemical compound CS(=O)(=O)OC[C@@H](OC(C)=O)[C@@H](OC)[C@H](OC)[C@@H](COS(C)(=O)=O)OC(C)=O KRWZZLLACQKPOW-AAVRWANBSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 210000003914 myeloid leukocyte Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU78GO1402A HU175923B (en) | 1978-05-03 | 1978-05-03 | Process for preparing 1,6-di-o-methanesulphonyl-3,4-di-o-methyl-d-mannitol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7903828L SE7903828L (sv) | 1979-11-04 |
| SE435497B true SE435497B (sv) | 1984-10-01 |
Family
ID=10996856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7903828A SE435497B (sv) | 1978-05-03 | 1979-05-02 | 1,6-dimetylsulfonyl-3,4-dimetyl-d-mannitol, farmaceutisk beredning och forfarandet for framstellning derav |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4235803A (en, 2012) |
| JP (1) | JPS5522661A (en, 2012) |
| AT (1) | AT361010B (en, 2012) |
| CA (1) | CA1112660A (en, 2012) |
| DE (1) | DE2917890A1 (en, 2012) |
| DK (1) | DK147069C (en, 2012) |
| FR (1) | FR2424928A1 (en, 2012) |
| GB (1) | GB2021570B (en, 2012) |
| HU (1) | HU175923B (en, 2012) |
| IL (1) | IL57196A (en, 2012) |
| IT (1) | IT1163674B (en, 2012) |
| NL (1) | NL7903475A (en, 2012) |
| SE (1) | SE435497B (en, 2012) |
| SU (1) | SU902663A3 (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5713719U (en, 2012) * | 1980-06-30 | 1982-01-23 | ||
| JPS6037582U (ja) * | 1983-08-24 | 1985-03-15 | 鮫島 康斎 | フレ−ム |
| JP3108511B2 (ja) * | 1992-02-27 | 2000-11-13 | 三菱レイヨン株式会社 | 不飽和アルデヒド及び不飽和カルボン酸合成用触媒の製造法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB891466A (en) * | 1958-04-24 | 1962-03-14 | Nat Res Dev | New methane sulphonic acid esters of polyols |
| CH381666A (de) * | 1958-04-24 | 1964-09-15 | Nat Res Dev | Verfahren zur Herstellung von Derivaten von polyhydrischen Alkoholen |
| GB945990A (en) * | 1962-01-29 | 1964-01-08 | Chinoin Gyogyszer Es Vegyeszet | Hexitol alkylsulphonic acid esters |
-
1978
- 1978-05-03 HU HU78GO1402A patent/HU175923B/hu unknown
-
1979
- 1979-04-26 US US06/033,492 patent/US4235803A/en not_active Expired - Lifetime
- 1979-05-01 IL IL57196A patent/IL57196A/xx unknown
- 1979-05-01 GB GB7915194A patent/GB2021570B/en not_active Expired
- 1979-05-02 SE SE7903828A patent/SE435497B/sv not_active IP Right Cessation
- 1979-05-02 DK DK180679A patent/DK147069C/da not_active IP Right Cessation
- 1979-05-02 FR FR7910985A patent/FR2424928A1/fr active Granted
- 1979-05-03 NL NL7903475A patent/NL7903475A/xx not_active Application Discontinuation
- 1979-05-03 IT IT22320/79A patent/IT1163674B/it active
- 1979-05-03 DE DE19792917890 patent/DE2917890A1/de active Granted
- 1979-05-03 SU SU762764296A patent/SU902663A3/ru active
- 1979-05-03 CA CA326,848A patent/CA1112660A/en not_active Expired
- 1979-05-03 AT AT330579A patent/AT361010B/de not_active IP Right Cessation
- 1979-05-04 JP JP5520079A patent/JPS5522661A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| HU175923B (en) | 1980-11-28 |
| NL7903475A (nl) | 1979-11-06 |
| DE2917890A1 (de) | 1979-11-15 |
| IL57196A0 (en) | 1979-09-30 |
| JPS5522661A (en) | 1980-02-18 |
| GB2021570A (en) | 1979-12-05 |
| GB2021570B (en) | 1982-06-23 |
| FR2424928A1 (fr) | 1979-11-30 |
| IT1163674B (it) | 1987-04-08 |
| FR2424928B1 (en, 2012) | 1982-08-20 |
| US4235803A (en) | 1980-11-25 |
| SU902663A3 (ru) | 1982-01-30 |
| CA1112660A (en) | 1981-11-17 |
| AT361010B (de) | 1981-02-10 |
| ATA330579A (de) | 1980-07-15 |
| DK180679A (da) | 1979-11-04 |
| DK147069B (da) | 1984-04-02 |
| SE7903828L (sv) | 1979-11-04 |
| DK147069C (da) | 1984-09-10 |
| IT7922320A0 (it) | 1979-05-03 |
| JPS576423B2 (en, 2012) | 1982-02-04 |
| DE2917890C2 (en, 2012) | 1987-10-29 |
| IL57196A (en) | 1982-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5663335A (en) | Immunosuppressive compounds and methods | |
| US5100883A (en) | Fluorinated esters of rapamycin | |
| US5221670A (en) | Rapamycin esters | |
| US5346893A (en) | Rapamycin 42-sulfonates and 42-(N-carbalkoxy) sulfamates useful as immunosuppressive agents | |
| US5233036A (en) | Rapamycin alkoxyesters | |
| US5164399A (en) | Rapamycin pyrazoles | |
| US5962516A (en) | Immunosuppressive compounds and methods | |
| US4939128A (en) | Ester of ascorbic acid 2-phosphate and pharmaceutical use | |
| US5358944A (en) | Rapamycin esters for treating transplantation rejection | |
| SK133096A3 (en) | Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them | |
| SE436648B (sv) | Analogiforfarande for framstellning av 5-(2-pyrroyl)-1,2-dihydro-3h-pyrrolo/1,2-a/pyrrol-1-karbonsyraderivat | |
| US5260299A (en) | Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents | |
| EP0009882B1 (en) | 2'-deoxy-5-fluorouridine derivatives, a process for producing the same and antitumor agents comprising the same | |
| CN108003027B (zh) | 1-o-咖啡酰奎宁酸、其衍生物、制备方法及其用途 | |
| SE435497B (sv) | 1,6-dimetylsulfonyl-3,4-dimetyl-d-mannitol, farmaceutisk beredning och forfarandet for framstellning derav | |
| US4539326A (en) | 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents | |
| US20060111327A1 (en) | Derivatives of triptolide having a high immunosuppressive effect and high water solubility, and uses thereof | |
| US4585589A (en) | Water-soluble alkanoyloxy and alkoxycarbonyloxy rifampicin derivatives, process for its preparation, intermediates, and its pharmaceutical composition as antibacterials | |
| CS203193B2 (en) | Method of producing n 1-glucofuranosid-6-yl-n 3-nitrosoureas | |
| RU2118311C1 (ru) | Производные бис-(фенил)этана и фармацевтическая композиция на их основе | |
| KR100202320B1 (ko) | 제약적으로 유용한 안트라센 화합물 | |
| PL101458B1 (pl) | Sposob wytwarzania nowych pochodnych dwuanhydroheksytolu | |
| JPS63264580A (ja) | ３−（２−ハロアルキル）−１，４−オキサチインおよび２−（２−ハロアルキル）−１，４−ジチイン | |
| GB2124213A (en) | Dithiolane derivatives | |
| US7589125B2 (en) | 2,4-dihydroxybenzoic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 7903828-7 Effective date: 19890525 Format of ref document f/p: F |